LON:IMM - Immupharma Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
GBX 28.70 +1.10 (+3.99 %)
(As of 05/24/2018 04:00 PM ET)
Previous CloseGBX 28.70
Today's RangeGBX 27 - GBX 30.60
52-Week RangeGBX 44 - GBX 193.74
Volume1.85 million shs
Average Volume817,845 shs
Market Capitalization£174.33 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A

About Immupharma (LON:IMM)

Immupharma logoImmuPharma plc, a pharmaceutical company, develops drug candidates based on peptide therapeutics to treat serious medical conditions. The company's lead product candidate is the Lupuzor, which is in Phase III clinical trials for the treatment of lupus, an autoimmune chronic inflammatory disease. Its other product candidates include IPP-204106, an anti-cancer nucleolin antagonis peptide program that has completed Phase I/IIa clinical trials to treat cancer; IPP-102199, which is in pre-clinical development stage to treat severe pain; IPP-201007 that is in early development stage for the treatment of inflammatory and allergic conditions, such as asthma and other respiratory disorders, rheumatoid arthritis, septic shock, and acute pancreatitis; and IPP-203101, a peptide-based antibiotic, which is in pre-clinical development stage for the treatment of lethal infections, including methicillin-resistant staphylococcus aureus and other hospital acquired infections. The company's discovery pipeline includes heterocyclic ureas scaffolds; and peptide to drug converting technology that enhances a peptide's plasma half-life and efficacy. ImmuPharma plc has collaboration arrangements with the Centre National de la Recherché Scientifique; and Institut National de la Sante et de la Recherche Medicale. The company was founded in 1999 and is headquartered in London, the United Kingdom.

Receive IMM News and Ratings via Email

Sign-up to receive the latest news and ratings for IMM and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biotechnology
Sub-IndustryN/A
SectorMedical
SymbolLON:IMM
CUSIPN/A
Phone+44-20-71524080

Debt

Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A

Profitability

EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net Margins-3,507.40%
Return on Equity-101.24%
Return on Assets-86.98%

Miscellaneous

EmployeesN/A
Outstanding Shares129,670,000

Immupharma (LON:IMM) Frequently Asked Questions

What is Immupharma's stock symbol?

Immupharma trades on the London Stock Exchange (LON) under the ticker symbol "IMM."

What price target have analysts set for IMM?

4 equities research analysts have issued 12-month target prices for Immupharma's shares. Their forecasts range from GBX 181 to GBX 237. On average, they expect Immupharma's stock price to reach GBX 199.67 in the next twelve months. View Analyst Ratings for Immupharma.

Who are some of Immupharma's key competitors?

Who are Immupharma's key executives?

Immupharma's management team includes the folowing people:
  • Mr. Dimitri F. Dimitriou M.Sc., Co-Founder, CEO & Director (Age 56)
  • Dr. D. Robert Henri Zimmer M.D., Ph.D., Co-Founder, Pres, Chief Scientific Officer & Director (Age 70)
  • Ms. Tracy Weimar BA, MBA, VP of Operations & Fin. and Company Sec.
  • Dr. Jean-Marie Geiger PharmD, MD, Head of Clinical Devel.
  • Mr. Nicholas Peter Kostopoulos, Lupuzor Director of Bus. Devel. - United States

Has Immupharma been receiving favorable news coverage?

News headlines about IMM stock have been trending somewhat positive on Thursday, according to Accern Sentiment. The research group ranks the sentiment of press coverage by analyzing more than twenty million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Immupharma earned a coverage optimism score of 0.02 on Accern's scale. They also gave news coverage about the company an impact score of 46.83 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock's share price in the next few days.

How do I buy shares of Immupharma?

Shares of IMM and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.

What is Immupharma's stock price today?

One share of IMM stock can currently be purchased for approximately GBX 28.70.

How big of a company is Immupharma?

Immupharma has a market capitalization of £174.33 million.

How can I contact Immupharma?

Immupharma's mailing address is 50 Broadway, LONDON, SW1H 0BL, United Kingdom. The company can be reached via phone at +44-20-71524080.


MarketBeat Community Rating for Immupharma (IMM)

Community Ranking:  3.6 out of 5 (star star star)
Outperform Votes:  174 (Vote Outperform)
Underperform Votes:  68 (Vote Underperform)
Total Votes:  242
MarketBeat's community ratings are surveys of what our community members think about Immupharma and other stocks. Vote "Outperform" if you believe IMM will outperform the S&P 500 over the long term. Vote "Underperform" if you believe IMM will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Immupharma (LON:IMM) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
4 Wall Street analysts have issued ratings and price targets for Immupharma in the last 12 months. Their average twelve-month price target is GBX 199.67The high price target for IMM is GBX 237 and the low price target for IMM is GBX 181. There are currently 4 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.003.003.003.00
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: GBX 199.67GBX 199.67GBX 174.75GBX 154

Immupharma (LON:IMM) Consensus Price Target History

Price Target History for Immupharma (LON:IMM)

Immupharma (LON:IMM) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetDetails
4/17/2018Northland SecuritiesReiterated RatingBuyView Rating Details
4/16/2018Berenberg BankReiterated RatingBuyView Rating Details
3/23/2018Northland Capital PartnersReiterated RatingBuyGBX 181View Rating Details
12/21/2017FinnCapReiterated RatingBuyGBX 237View Rating Details
4/20/2017Panmure GordonReiterated RatingBuyGBX 100View Rating Details
(Data available from 5/24/2016 forward)

Earnings

Dividends

Immupharma (LON:IMM) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Immupharma (LON IMM) Insider Trading and Institutional Ownership History

Insider Trading History for Immupharma (LON:IMM)

Immupharma (LON IMM) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
(Data available from 1/1/2013 forward)

Headlines

Immupharma (LON IMM) News Headlines

Source:
DateHeadline
What Investors Should Know About ImmuPharma plc’s (LON:IMM) Financial StrengthWhat Investors Should Know About ImmuPharma plc’s (LON:IMM) Financial Strength
finance.yahoo.com - May 17 at 10:32 AM
Berenberg Bank Reaffirms "Buy" Rating for Immupharma (IMM)Berenberg Bank Reaffirms "Buy" Rating for Immupharma (IMM)
www.americanbankingnews.com - April 17 at 4:17 PM
BRIEF-Immupharma Announces Topline Results Of Lupuzor Pivotal Phase III TrialBRIEF-Immupharma Announces Topline Results Of Lupuzor Pivotal Phase III Trial
www.reuters.com - April 17 at 10:34 AM
When Should You Buy ImmuPharma plc (LON:IMM)?When Should You Buy ImmuPharma plc (LON:IMM)?
finance.yahoo.com - April 17 at 10:34 AM
Immupharma (IMM) Rating Reiterated by Northland SecuritiesImmupharma (IMM) Rating Reiterated by Northland Securities
www.americanbankingnews.com - April 17 at 8:07 AM
Immupharmas (IMM) "Buy" Rating Reaffirmed at Northland SecuritiesImmupharma's (IMM) "Buy" Rating Reaffirmed at Northland Securities
www.americanbankingnews.com - April 7 at 11:01 PM
ImmuPharma plc’s (LON:IMM) Path To ProfitabilityImmuPharma plc’s (LON:IMM) Path To Profitability
finance.yahoo.com - March 31 at 10:05 AM
Northland Securities Reiterates "Buy" Rating for ImmuPharma (IMM)Northland Securities Reiterates "Buy" Rating for ImmuPharma (IMM)
www.americanbankingnews.com - March 23 at 4:08 PM
ImmuPharma (IMM) Stock Rating Reaffirmed by Northland Capital PartnersImmuPharma (IMM) Stock Rating Reaffirmed by Northland Capital Partners
www.americanbankingnews.com - March 23 at 3:13 PM
Are ImmuPharma plc’s (LON:IMM) Interest Costs Too High?Are ImmuPharma plc’s (LON:IMM) Interest Costs Too High?
finance.yahoo.com - February 2 at 8:36 AM
ImmuPharma Raises GBP10 Million To Support Future Investments (ALLISS)ImmuPharma Raises GBP10 Million To Support Future Investments (ALLISS)
www.morningstar.co.uk - January 25 at 8:35 AM
Was ImmuPharma plc’s (LON:IMM) Earnings Growth Better Than The Industry’s?Was ImmuPharma plc’s (LON:IMM) Earnings Growth Better Than The Industry’s?
finance.yahoo.com - January 25 at 8:35 AM
ImmuPharma (IMM) Receives New Coverage from Analysts at FinnCapImmuPharma (IMM) Receives New Coverage from Analysts at FinnCap
www.americanbankingnews.com - December 25 at 9:26 AM
ImmuPharmas (IMM) "Buy" Rating Reiterated at FinnCapImmuPharma's (IMM) "Buy" Rating Reiterated at FinnCap
www.americanbankingnews.com - December 23 at 5:34 PM
ImmuPharma Plc :IMM-GB: Earnings Analysis: For the six months ended June 30, 2017 : November 22, 2017ImmuPharma Plc :IMM-GB: Earnings Analysis: For the six months ended June 30, 2017 : November 22, 2017
finance.yahoo.com - November 21 at 8:01 PM
ImmuPharma Nets Over GBP5.0 Million In Completed Lanstead Agreement (ALLISS) - London South East (blog)ImmuPharma Nets Over GBP5.0 Million In Completed Lanstead Agreement (ALLISS) - London South East (blog)
www.lse.co.uk - October 6 at 11:12 PM
Is This A Catalyst To Buy ImmuPharma plc (AIM:IMM)?Is This A Catalyst To Buy ImmuPharma plc (AIM:IMM)?
finance.yahoo.com - October 4 at 5:22 PM
Northland Securities Reaffirms Buy Rating for ImmuPharma PLC (IMM)Northland Securities Reaffirms Buy Rating for ImmuPharma PLC (IMM)
www.americanbankingnews.com - October 1 at 9:52 AM
ImmuPharma Prepares Regulatory Filings Ahead Of Lupuzor Trial ResultsImmuPharma Prepares Regulatory Filings Ahead Of Lupuzor Trial Results
www.morningstar.co.uk - September 26 at 10:30 AM
ImmuPharma PLC (IMM) Stock Rating Reaffirmed by Northland SecuritiesImmuPharma PLC (IMM) Stock Rating Reaffirmed by Northland Securities
www.americanbankingnews.com - September 23 at 12:44 PM
Immupharma Confident As Phase III Lupuzor Trial On TrackImmupharma Confident As Phase III Lupuzor Trial On Track
www.morningstar.co.uk - September 22 at 11:57 PM
ImmuPharma PLC (IMM) Stock Rating Reaffirmed by Northland Capital PartnersImmuPharma PLC (IMM) Stock Rating Reaffirmed by Northland Capital Partners
www.americanbankingnews.com - September 21 at 3:10 PM
Is ImmuPharma plc (AIM:IMM) Undervalued?Is ImmuPharma plc (AIM:IMM) Undervalued?
finance.yahoo.com - September 6 at 7:48 PM
ImmuPharma PLC (LON:IMM) PT Raised to GBX 181 at Northland SecuritiesImmuPharma PLC (LON:IMM) PT Raised to GBX 181 at Northland Securities
www.americanbankingnews.com - July 1 at 12:36 PM
ImmuPharma Recruits And Doses 200 Patients In Phase III Lupuzor TrialImmuPharma Recruits And Doses 200 Patients In Phase III Lupuzor Trial
www.morningstar.co.uk - June 30 at 7:58 PM
IMM. Reading back t-IMM. Reading back t-
www.lse.co.uk - June 24 at 11:18 PM
ImmuPharma 2016 Loss Widens As It Progresses Lupus Phase III TrialImmuPharma 2016 Loss Widens As It Progresses Lupus Phase III Trial
www.morningstar.co.uk - June 2 at 8:09 AM
UPDATE: ImmuPharma Raises GBP4.1 Million, Seeks Partners For Lupuzor (ALLISS)UPDATE: ImmuPharma Raises GBP4.1 Million, Seeks Partners For Lupuzor (ALLISS)
www.morningstar.co.uk - March 11 at 12:07 AM
BRIEF-ImmuPharma says update on lupuzor pivotal phase iii studyBRIEF-ImmuPharma says update on lupuzor pivotal phase iii study
www.reuters.com - January 25 at 7:18 PM
Update on Lupuzor Pivotal Phase III Study - London South East (registration) (blog)Update on Lupuzor Pivotal Phase III Study - London South East (registration) (blog)
www.lse.co.uk - December 23 at 11:10 PM
Legal & General Buys 3.4% Stake In Junior Drug Firm ImmuPharma (ALLISS)Legal & General Buys 3.4% Stake In Junior Drug Firm ImmuPharma (ALLISS)
www.morningstar.co.uk - November 9 at 6:56 AM
Close of Accelerated BookbuildClose of Accelerated Bookbuild
www.lse.co.uk - October 22 at 5:18 PM
ImmuPharma Investor To Place Shares, Company To Raise GBP800,000 (ALLISS)ImmuPharma Investor To Place Shares, Company To Raise GBP800,000 (ALLISS)
www.morningstar.co.uk - October 21 at 5:40 PM

SEC Filings

Immupharma (LON:IMM) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Social activity is not available for this stock.

Financials

Financials are not available for this stock.

Chart

Immupharma (LON IMM) Stock Chart for Thursday, May, 24, 2018

Loading chart…

This page was last updated on 5/24/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.